60 days novo and other euro pharmas involved

Sydney - Monday - October 17: (RWE Aust Business News) - CBio Ltd
(ASX:CBZ) has received the final report for its phase IIa clinical trial
in rheumatoid arthritis (RA) patients.
The study evaluated the efficacy and safety of XToll in 155
patients with moderate to severe rheumatoid arthritis despite treatment
with methotrexate (MTX).
Patients on the trial were randomised to receive 75mg of XToll,
25mg of XToll or placebo via subcutaneous injection twice-weekly for 24
weeks.
Efficacy was assessed by the American College of Rheumatology
(ACR) standardised measure of improvement in rheumatoid arthritis signs
and symptoms.
CBio's chairman, Stephen Jones, said that final data supports the
Board's view that XToll is a potential new therapy for autoimmune and
inflammatory diseases.
"In this study we have demonstrated improvement in a number of
disease activity areas and we have identified a number of interesting
trends," he said.
"The Board's view is that further studies of XToll in autoimmune
disorders are appropriate.
"The Board believes this a potential first-in-class drug with a
novel mechanism of action," Mr Jones said.
CBio will now deliver the final study report to Novo Nordisk,
which will signify the completion of the workplan as contemplated under
their option agreement.
Novo Nordisk will have up to 60 days to exercise its option to
negotiate a licensing deal for the XToll technology.